Benchmark Issues Positive Forecast for DexCom (NASDAQ:DXCM) Stock Price

DexCom (NASDAQ:DXCM) had its price target increased by analysts at Benchmark from $77.00 to $82.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical device company’s stock. Benchmark’s price objective points to a potential downside of 0.63% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of DexCom in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target on the stock. TD Cowen reaffirmed a “buy” rating and issued a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Mizuho increased their price target on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, Truist Financial set a $93.00 price objective on DexCom and gave the company a “buy” rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $85.58.

DexCom Stock Performance

DXCM opened at $82.52 on Friday. DexCom has a 12-month low of $54.11 and a 12-month high of $87.00. The firm has a market capitalization of $31.84 billion, a P/E ratio of 34.96, a price-to-earnings-growth ratio of 1.24 and a beta of 1.45. The stock’s 50 day moving average price is $72.91 and its two-hundred day moving average price is $69.10. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.48 EPS. On average, equities analysts forecast that DexCom will post 2.57 earnings per share for the current year.

Insider Activity

In related news, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 98,506 shares of company stock valued at $7,205,258. Corporate insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DXCM. Trust Co. of Vermont increased its holdings in shares of DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after acquiring an additional 145 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in shares of DexCom by 15.4% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock valued at $77,000 after purchasing an additional 153 shares during the period. V Square Quantitative Management LLC lifted its position in DexCom by 1.8% during the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after purchasing an additional 172 shares during the period. Essex Financial Services Inc. boosted its position in DexCom by 5.7% in the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after purchasing an additional 175 shares in the last quarter. Finally, Keel Point LLC raised its position in shares of DexCom by 3.1% in the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after acquiring an additional 193 shares during the period. Institutional investors own 97.75% of the company’s stock.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom exceeded second-quarter expectations, reporting adjusted EPS of $0.70 versus the $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13% year over year, while EPS rose from $0.48 a year earlier. Reuters article
• Positive Sentiment: The company raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by sustained demand for continuous glucose monitoring devices. Management is targeting nearly 50% U.S. adoption of the G7 15-Day sensor by year-end. Seeking Alpha outlook article
• Positive Sentiment: Worldwide revenue growth included $933 million from the U.S., up 11%, with international sales also contributing to the overall 12% organic growth rate. The raised forecast and quarterly beat initially sent shares higher in extended trading. GuruFocus earnings highlights
• Positive Sentiment: UBS reaffirmed its Buy rating and maintained a $96 price target, implying substantial upside from the referenced share price. Benzinga analyst coverage
• Neutral Sentiment: Although the earnings news is favorable, the subsequent pullback may reflect profit-taking after the initial rally or investor caution about expectations at a valuation near 32 times earnings.
• Negative Sentiment: Medical-device companies continue to face potential margin pressure from tariffs and inflation, risks that could temper the benefit of strong underlying demand. Zacks medical-product outlook

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.